Using HER2-targeted drugs (such as trastuzumab, pertuzumab, lapatinib, and neratinib) can make a contribution to improving the treatment effectiveness, reducing the risks of recurrence and mortality, and prolonging survival for HER2-positive breast cancer patients [8–10]. This evidence concerns the gene ERBB2 and breast cancer.